Abstract: A method for manufacturing a detector of a first and a second incident ionizing radiation including determining the abscissa em of a point of intersection between a first and a second curve, with the first and second curves representing the evolution of the number of photons or electrical charges generated per second by a transducing material as a function of the total thickness of an amplifying material when the transducing material is irradiated, through this thickness of transducing material, by the first and second incident ionizing radiation, respectively; then selecting the total thickness of amplifying material between 0.9 em and 1.1 em and producing the detector with the selected thickness of amplifying material.

Abstract: The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

Abstract: The invention relates to a device (2, 4) for homogenizing a radiofrequency field, for magnetic resonance imaging, of a given wavelength emitted by a volumetric antenna, comprising at least one continuous metal track (8) with a total length of between 50% and 75% of the wavelength of the radiofrequency field, the metal track comprising two end segments extending in mutually parallel directions and a main portion extending between the two end segments and comprising several local deformations identical to one another and connected to one another in series by at least one at least partially rectilinear connection portion (14) in such a way as to provide the homogenizing device (2, 4) with an electric dipole property, the homogenizing device having a fundamental frequency higher than the frequency corresponding to the wavelength of the radiofrequency field.

Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.

Abstract: It is disclosed anti-BTN3A activating antibody fragments that specifically bind to BTN3A and activate the cytolytic function of V?9/V?2 T cells. The disclosure more specifically relates to specific anti-BTN3A binding proteins comprising such activating antibody fragments and their use in the manufacturing of novel drugs for use in treating cancer disorders, in particular cancers susceptible to be treated with activated ?? T cells.

Abstract: The invention concerns a system and method for reconstructing a physiological signal of an artery/tissue/vein system of an organ in a surface space. Said method is implemented by processing means of a processing unit of a functional imaging analysis system, and comprises a step for reconstructing said physiological signal from a piece of experimental data of a region of interest comprising an elementary volume—called a voxel—of said organ and a surface mesh describing said surface space. The invention differs from known methods in particular in terms of the high accuracy of same and the robustness thereof to noise.

Abstract: The present invention pertains to the field of nanoimprint lithography (NIL) processes and more specifically to a soft NIL process used for providing a sol-gel patterned layer on a substrate. Specifically, this process comprises a step of adjusting the solvent uptake of the sol-gel film to 10 to 50% vol., preferably between 15 and 40% vol., by varying the relative pressure of the solvent while a soft mould is applied onto the substrate coated with the sol-gel film.

Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the models in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.

Abstract: The present invention relates to antimicrobial peptides, variants and chemical analogues thereof; in particular, a peptide of 20 amino acids, named Michelicin, having the sequence RVCVRICRNGRCYRRCWNT, derived from a longer precursor with a BRICHOS domain from the marine worm Capitella. The peptide has several cysteines which form disulfide bridges and provide stability in salt conditions. Several derivatives and analogues were produced. The peptide and the derivatives show antimicrobial activity against a wide range of bacteria. The application also concerns nucleic acid sequences encoding these, pharmaceutical composition and to their use as a drug, preservative and disinfectant.

Abstract: The invention relates to a material for use as a pad in high field and/or very high field magnetic resonance imaging instrument, comprising at least one polar solvent having a melting point of 14° C. to 50° C., a dispersant and a dielectric charge. The invention relates also to a pad used in field of high field and/or very high field magnetic resonance imaging made of at least such a material.

Abstract: In one aspect the application relates to a computing system for providing data for modelling a human brain comprises a database including a plurality of datasets (or allow access to a plurality of datasets), each dataset including at least a dynamical model of the brain including at least one node and a neurodataset of a neuroimaging modality input. The at least one node include a representation of a local dynamic model and a parameter set of the local dynamic model.

Abstract: A solid organic material comprising at least one amphiphilic block copolymer of the methacrylic type, the block copolymer being dispersed in a polymer matrix, the block copolymer having a number-average molar mass (Mn) greater than or equal to 20 000 g/mol; a method for preparing said solid organic material; use of said solid organic material for antibacterial, antimicrobial, antiviral, anti-inflammatory and/or antifungal applications; a coating comprising said solid organic material.

Abstract: The method of simulating a human brain neural field in a computerized platform modelling various zones of a human brain and connectivity between the zones includes: providing the computerized platform modelling the various zones of the human brain and connectivity between the zones; acquiring three-dimensional anatomical structural imaging data of a folded surface of a cortex of a brain of a human patient; personalizing the computerized platform according to the structural data; providing an equation describing a spatiotemporal evolution of the neural field and loading the equation in the computerized platform; performing a projection of the surface of the cortex of the brain of the patient on a spherical surface domain; simulating the neural field in the spherical domain; and translating the simulated neural field in the spherical domain in the cortical domain.

Abstract: A method for operating a sense amplifier in a one-switch one-resistance (1S1R) memory array, includes: generating a regulated full voltage and a regulated half voltage; applying the regulated full voltage and regulated half voltage to selected and unselected bit lines of the 1S1R memory array during read operations as an applied read voltage; and inducing and compensating for a sneak-path current during read operations by adjusting the applied read voltage based on the cell state of an accessed bit cell and an amplitude of the sneak-path current.

Abstract: The present invention relates to an optically pure (+) or (?) enantiomer of a ruthenium complex having formula (I) as well as the preparation method of said enantiomer, and uses thereof as catalyst, in particular in asymmetric olefin metathesis.

Abstract: The deep brain stimulation system has at least four stimulation pairs of electrodes. Each stimulation pair of electrodes provides an electric stimulation at a carrier frequency. The mean value between the carrier frequency of any first stimulation pair of electrodes and the carrier frequency of any second stimulation pair of electrodes defines a first mean carrier frequency. The mean value between the carrier frequency of any third stimulation pair of electrodes and the carrier frequency of any fourth stimulation pair of electrodes defines a second mean carrier frequency. The difference between the first and second mean carrier frequencies is equal to or greater than 200 Hz.

Abstract: The invention relates to Variable Domain of Camelid Heavy Chain-only (VHH) molecules which bind TfR and the uses thereof e.g., to transport molecules of pharmaceutical or diagnostic interest into cells and in organs, in pathological conditions including cancer.

Abstract: The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. The inventors have demonstrated that the adoptive transfer of Tregs previously incubated with soluble lymphotoxin-? receptor in mice protects from dextran sodium sulfate (DSS)-induced colitis. Thus, the number of cells to be injected in adoptive transfer may be reduced and a transfection or transduction step avoided, which represents a technical facilitation.

Abstract: The instant invention relates to thionolactone compounds useful as comonomers to introduce weak bonds for polymer degradation or functionalization. The invention is also directed to processes for the preparation of said compounds, notably by thionation of the corresponding lactones. The invention is furthermore directed to uses of said thionolactones as comonomers, copolymers made from these comonomers, and processes for the preparation of said copolymers.

Abstract: The method for determining an onset time and an excitability of a brain region that is not observed as recruited or not recruited in a seizure activity of an epileptic patient brain includes: providing a dynamical model of a propagation of an epileptic seizure in the brain networks; providing a statistical model which defines the probability of generating sets of observations of the state of the brain networks by said dynamical model; training the dynamical model of the propagation of an epileptic seizure using the statistical model and the data set of observations of the training cohort; and inverting the trained dynamical model and inferring the onset time and excitability of a third region from the onset time that is observed for the first and second regions using the statistical model.